Carmence Ho
- Neutrophil, Myeloperoxidase and Oxidative Mechanisms
- Chronic Myeloid Leukemia Treatments
- Macrophage Migration Inhibitory Factor
- Immune Cell Function and Interaction
- Cancer Research and Treatments
- Cell Adhesion Molecules Research
- Immune cells in cancer
- Cancer Immunotherapy and Biomarkers
- Structural Behavior of Reinforced Concrete
- Peptidase Inhibition and Analysis
- Melanoma and MAPK Pathways
- CAR-T cell therapy research
- Monoclonal and Polyclonal Antibodies Research
- Phagocytosis and Immune Regulation
- Acute Myeloid Leukemia Research
- Ferroptosis and cancer prognosis
- IL-33, ST2, and ILC Pathways
- Cytokine Signaling Pathways and Interactions
- Immunotherapy and Immune Responses
- NF-κB Signaling Pathways
- Veterinary medicine and infectious diseases
- Lymphoma Diagnosis and Treatment
NGM Biopharmaceuticals (United States)
2022-2024
We recently reported that resistance to PD-1 blockade in a refractory lung cancer-derived model involved increased collagen deposition and the collagen-binding inhibitory receptor leukocyte-associated immunoglobulin-like 1 (LAIR1). Thus, we hypothesized LAIR1 cooperated suppress therapeutic response. In this study, report is associated with tumor stroma highly expressed by intratumoral myeloid cells both human tumors mouse models of cancer. Stroma-associated exhibit suppressive phenotype...
Solid tumors are dense three-dimensional (3D) multicellular structures that enable efficient receptor-ligand trans interactions via close cell-cell contact. Immunoglobulin-like transcript (ILT)2 and ILT4 related immune-suppressive receptors play a role in the inhibition of myeloid cells within tumor microenvironment. The relative contribution ILT2 to immune context solid tissue has not been fully explored. We present evidence both contribute inhibition. found although inhibits cell...
Abstract Background: Myeloid immune suppression in the tumor microenvironment is known to contribute evasion. ILT2 (aka LILRB1) and ILT4 LILRB2) are distinct ITIM-containing immunosuppressive receptors that recognize shared MHC-I ligands. Both highly expressed on infiltrating myeloid cells, while also tumor-associated T NK cells. Furthermore, both upregulated patients who do not respond cell checkpoint inhibitor therapy, implicating these as potential resistance mechanisms. Given their...
<p>Supplementary Methods, Tables, and Figure Legends</p>
<p>Supplementary Figure S5</p>
<p>Supplementary Figure S8</p>
<p>Supplementary Methods, Tables, and Figure Legends</p>
<p>Supplementary Figure S4</p>
<p>Supplementary Figure S9</p>
<p>Supplementary Figure S4</p>
<p>Supplementary Figure S7</p>
<p>Supplementary Figure S9</p>
<p>Supplementary Figure S7</p>
<p>Supplementary Figure S6</p>
<p>Supplementary Figure S8</p>
<p>Supplementary Figure S5</p>
<p>Supplementary Figure S6</p>
<p>Supplementary Figure S10</p>
<p>Supplementary Figure S11</p>
<p>Supplementary Figure S13</p>
<p>Supplementary Figure S1</p>
<p>Supplementary Figure S1</p>
<p>Supplementary Figure S2</p>
<p>Supplementary Figure S16</p>
<p>Supplementary Figure S15</p>